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Egon Hagena
aKORFOR – Center for Alcohol and Drug Research, Stavanger University Hospital, Stavanger, Norway; bThe Norwegian Centre for Movement
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University of Bergen, Bergen, Norway; dDivision of Psychiatry, Stavanger University Hospital, Stavanger, Norway; eCentre for Alcohol and
Drug Research, Aarhus University, Aarhus, Denmark
ABSTRACT
Introduction: Polysubstance use is a prevalent substance use pattern with adverse effects on psycho-
logical distress and diminished treatment outcomes. Although polysubstance use often dominates clin-
ical practice, the trajectories of substance use and psychological distress in the initial phase of
treatment have been subject to few empirical investigations.
Material and Methods: 141 patients initiating inpatient or outpatient treatment for substance use dis-
order were followed for 12months, using multiple assessments. We assessed psychological distress and
substance use at baseline and at 3-, 6-, and 12-month follow-up visits. We implemented an SMS tracker
of substance use during follow-up to reduce the impact of missing data.
Results: Stable abstinence was associated with a lower baseline SCL-90-R score, as well as a more rapid
symptomatic decline during the first 3months of abstinence. Unstable abstinence was associated with
higher GSI scores at baseline, but also with a significant drop in scores across the follow-up period.
Relapse was associated with an initial drop in GSI scores, but a subsequent increase in GSI scores at later
follow-ups.
Conclusions: Most participants had a rapid reduction of psychological distress during the first
3months of abstinence. Elevated levels of psychological distress may indicate an increased risk of drug
use or relapse and should be monitored carefully. Our findings highlight the importance of early
screening for psychological distress in SUD treatment, and advocate the use of tentative diagnostic
procedures in the early phase of treatment of PSUD.
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Substance use disorder (SUD) is a debilitating disorder, often
resulting in loss of academic achievement, social isolation,
and often severe effects on mental and physical health
(American Psychiatric Association 2013; Martin et al. 2014;
Kelly, Evans-Whipp, et al. 2015; Heradstveit et al. 2017).
While polysubstance dependence is not in the DSM-5 (Hasin
et al. 2013), polysubstance use is common in clinical samples
(Bhalla et al. 2017), and polysubstance use patterns is often
seen in patients seeking treatment for mono-drug disorders
(Brooner et al. 1997; Staines et al. 2001; Palamar et al. 2018;
Timko et al. 2018; Choi and DiNitto 2019). Polysubstance use
disorder (PSUD) in this context refers to the use of multiple
substances as part of a pattern of problematic substance use,
in which the patient meets criteria for substance use disorder
for some, but not necessarily all substances used.
In clinical practice, a quintessential goal of treatment is con-
tinued abstinence. Best-practice guidelines suggest appropriating
a tailored and personalized approach to treatment, which often
entails including a patient’s social, psychological and medical
status in the planning of treatment (Kleber et al. 2007). SUD-
related subjective psychological distress is especially prominent
among patients with PSUD, both in clinical and nonclinical
samples (Hoxmark et al. 2010; Connor et al. 2014; Kelly, Chan,
et al. 2015). PSUD is also associated with poor treatment out-
comes, and higher frequencies of comorbid mental disorders,
including affective disorders, anxiety, and positive psychotic
symptoms (Riehman et al. 2002; Bakken et al. 2007; Dutra et al.
2008; Connor et al. 2013; Quek et al. 2013; Salom et al. 2016).
These adverse outcomes have been argued to be a result of dos-
e–response relationship where increasing numbers of substances
used result in more adverse effects on psychological health
(Andreas et al. 2015), an association which might be especially
prominent during periods of active drug use (Tomasson and
Vaglum 1997; Booth et al. 2010; Andreas et al. 2015).
However, when SUD patients enter treatment, psycho-
logical symptoms tend to improve considerably as a result of
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continued abstinence, especially in the patients with the
highest severity of drug or alcohol use disorders (Hoxmark
et al. 2010). Our group has previously found alleviation of
psychological distress, increased quality of life, and improved
neurocognitive functioning after 12months of abstinence
(Hagen et al. 2017). Reduced psychological distress has also
been demonstrated in patients who reduce substance use
over 3 years (Booth et al. 2010). Abstinence has also been
associated with long-term gradual alleviation of mental dis-
tress among patients with pSUD at 2-, 6-, and 10-year fol-
low-ups (Tomasson and Vaglum 1997; Bakken et al. 2007;
Andreas et al. 2015).
Despite the positive effects of abstinence, recovery is not
a stable or static state (De Soto et al. 1985). Little is known
about the recovery process during the initial phases of
abstinence among patients with pSUD (Gossop et al. 2006;
Dennis et al. 2007). Previous studies have demonstrated that
recovery from psychological distress may be evident follow-
ing abstinence periods exceeding 6months, and that psycho-
logical distress may continue to abate across several years
(Gossop et al. 2006; Andreas et al. 2015; Hagen et al. 2017).
However, acute-phase data from the early stages of
abstinence are still sparse and the interaction between psy-
chological distress and abstinence/recovery remain underex-
plored. Improved knowledge about the course and timing of
symptom alleviation during the recovery of polysubstance
abuse could help equip clinicians to better support patients
through what is known to be a very vulnerable phase with a
high risk of treatment dropout (Stark 1992; Passos and
Camacho 2000). The aim of our study was therefore to pro-
vide a detailed account of the trajectory of psychological dis-
tress, both during the acute phase of treatment and over
12months. We hypothesized that greater alleviation of psy-
chological distress would be related to more stable patterns
of abstinence.
2. Methods
2.1. Study design and patient characteristics
This study used data from the Norwegian Stayer study, a
prospective cohort study of the course and timing of neuro-
cognitive and psychosocial recovery of patients with poly-
substance use (Hagen et al. 2016). We recruited patients
from inpatient treatment facilities (N¼ 82), outpatient treat-
ment facilities (N¼ 52), and private treatment facilities
(N¼ 7) in the Stavanger University Hospital catchment area.
Both outpatient and inpatient treatment in Norway is regu-
lated by the health authorities through national guidelines,
and all patients are provided interdisciplinary services,
including psychological, medical and social assistance, in
their recovery process. See Andersson, Steinsbekk, et al.
(2018) for more details regarding the structure of Norwegian
SUD-treatment. To access specialized treatment for SUDs
within the Norwegian public health service, patients must
fulfill the criteria for a diagnosis F1x.1 – harmful use, or
F1x.2 – dependency syndrome, as defined by the ICD-10
(World Health Organization 1992). For this study, polysub-
stance users were defined as patients with SUD, who
reported use of multiple substances within the last year
before inclusion. The Stayer study was approved by the
Regional Ethical Committee (REK 2011/1877).
2.2. Inclusion criteria
Inclusion criteria included: (a) signed written informed con-
sent; (b) polysubstance use as defined by the above diagnos-
tic criteria; (c) participant initiating a course of treatment
within the substance abuse treatment services; (d)
age >16 years.
2.3. Participant characteristics
A total of 208 patients were recruited consecutively from the
Stavanger University Hospital catchment area between
March 2012 and January 2016. Patients received NOK 400
in compensation for their time at baseline testing.
Of the 208 patients in the Stayer cohort, 44 patients were
omitted from this study because of single-substance use (e.g.
alcohol or cannabis) or a nondrug-related addiction (e.g.
gambling disorder), leaving 164 patients fulfilling the criteria
for the current study. During the follow-up period, 11
(6.7%) patients dropped out of the study, leaving 153 eligible
patients. By the 12-month follow-up, 12 of these patients
had withdrawn or were unavailable for evaluation, leaving a
final study cohort of 141 patients who completed every fol-
low-up (86% of eligible patients).
2.4. Procedures
At baseline, trained members of the Stayer study group
performed neurocognitive, psychological, and social func-
tioning assessments of every participant. This comprehen-
sive assessment was repeated at 12months. Follow-ups at 3
and 6months comprised a smaller subset of measures
assessing substance use and psychological and social func-
tioning. To limit the rate of attrition, comprehensive efforts
were made to ensure continued participation (Svendsen
et al. 2017).
We implemented an SMS tracker in addition to the main
follow-ups (Svendsen et al. 2017). Participants received an
automated text message every two weeks, to which they
replied with information about their current substance use
and treatment status. This procedure was implemented to
inform missing data and increase the temporal density of
the data gathered. The automated SMS service contained
two items: (1) “How much have you used drugs in the last
two weeks?” (Likert scale: 0¼Not at all, 1¼Very little,
2¼ Little, 3¼ Some, 4¼A lot, 5¼Considerably), and (2)
“Are you currently in treatment?” (“yes” or “no”).
2.5. Assessment
We gathered information about demographic variables, clin-
ical history, lifestyle factors, and social functioning using a
semi-structured interview. We used the consumption items
from the Drug Use Disorders Identification Test (DUDIT-
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C) and the Alcohol Use Disorders Identification Test
(AUDIT-C) (Babor et al. 1989; Berman et al. 2005) to assess
and track substance use. For the DUDIT-C, a cutoff score
>1 was used as a definition of current substance use.
Although AUDIT-C scores of >3 for women and >4 for
men have optimal sensitivity and specificity for problematic
alcohol use in the general population (Bush et al. 1998), a
cutoff score of 5 was used as a definition of problematic
alcohol use for this study. This higher cutoff score has previ-
ously been used to identify unhealthy alcohol use in at-risk
populations to limit the risk of false positives (Rubinsky
et al. 2013; Williams et al. 2014).
We measured general psychological distress using the
Symptoms Checklist 90 – Revised (SCL-90-R), a 90-item
self-report measure (Derogatis 1994). We scored items on a
five-point Likert scale ranging from 0 (Not at all) to 4
(Severe). The checklist yields nine symptom dimension
subscales: Somatization, Obsessive-Compulsive Disorder,
Interpersonal Sensitivity, Depression, Anxiety, Hostility,
Phobic Anxiety, Paranoid Ideation, and Psychoticism, in
addition to a global severity index (GSI). The SCL-90-R is
widely used in clinical practice and research and is a valid
instrument for assessing general psychological distress in
SUD patients (Bergly et al. 2014).
2.6. Data quality and missing data
All 141 participants attended the 12-month follow-up visit.
However, 41 patients did not attend the 3- and/or 6-month
visits, resulting in missing data.
2.7. Definitions
We used data from the AUDIT-C, DUDIT-C, and the SMS
tracker to assess the progression of substance use through-
out 12months. We used SMS data to inform missing data
for the 3- and 6-month visits. An answer of 1 on the
SMS question was used as an indication of drug use. Based
on these data, patients were divided into three groups: (1)
the Stable abstinence group who reported persistent abstin-
ence over the full 12-month period (i.e. no substance use
episodes reported during the follow up time); (2) the
Unstable abstinence group who reported abstinence at the
12-month assessment, but also reported substance use epi-
sodes during the follow-up period (i.e. score above cutoff
on AUDIT-C or DUDIT-C during follow up, but below
cutoff on the 12month-assessment); and (3) the Relapse
group who had relapsed at the 12-month evaluation.
Relapse was defined as a positive screening with either
AUDIT-C or DUDIT-C at the 1-year follow up visit. The
inclusion of the category “unstable abstinence” was based
on a common clinical observations; patient who manage to
recover from their PSUD, both in terms of drug use and
successful recovery of social and psychological variables,
often have single drug use-episodes during the recov-
ery phase.
2.8. Statistical analysis
We analyzed data using IBM SPSS v. 25 for PC and
GPower 3 (Faul et al. 2007). We defined statistical signifi-
cance as p-values <0.05 (two-tailed). First, assumptions were
evaluated using Q-Q plots and inspecting the residuals. We
used t-tests to check for gender differences in SCL-90-R
scores. Linear regression was used to assess the association
between baseline SCL-90-R GSI scores (dependent variable)
and age, gender, and age of drug debut (independ-
ent variables).
We examined longitudinal data using a linear mixed
model (LMM) with maximum likelihood estimation to assess
between-group differences on SCL-90-R GSI over the year.
We chose LMM to limit the impact of type 1 errors, and
fully use the available data. We included random intercept
for each patient and slope as they enhanced the model fit
(evaluated using Akaike’s information criteria and Schwarz’s
Bayesian criterion). The main parameters of interest were
the fixed interaction term between progression groups and
time. An unadjusted model, with SCL-90-R GSI scores as a
dependent variable, and time, progression type (stable
abstinence, unstable abstinence, or relapse), and an inter-
action term (progression type time) were fitted. We also
fitted an adjusted model, which included the fixed variable
education (in years). For the repeated measure (SCL-90-R
GSI), the unstructured covariance structure was assumed, as
this yielded the least amount of error and the best model fit.
We calculated the estimated marginal means using Sidak’s
adjustment for multiple testing. To gauge within-group dif-
ferences in SCL-90-R GSI scores between each follow-up
visit, separate LMMs were fitted for each group. In these
analyses, SCL-90-R was the dependent variable, while time
and education (in years) served as fixed effects. We com-
puted within-group pre–post effect sizes using Cohen’s d,
with pooled pre- and post-SD adjustment for sample size.
3. Results
3.1. Participant characteristics
Table 1 summarizes the demographic variables at baseline.
Participants were predominantly male, with a mean age of
27.5 (standard deviation [SD]¼ 7.7) years. Participant age
ranged widely (16–51 years). The participants were all poly-
substance users, with a mean duration of drug use of 14.5
(SD ¼ 7.8) years. Although the self-reported number of
Table 1. Baseline demographic and clinical variables for included patients
from the Norwegian Stayer study cohort (N¼ 141).
Mean (SD) Min/max
Age 27.5 (7.7) 16/51
Male/female 92/49 –
Education 12.3 (2.0) 3/18
Permanent housing, n (%) 80 (56.7) –
Stable income, n (%) 91 (64.5) –
Working, n (%) 23 (16.3) –
Age of drug debut 13.1 (2.2) 8/23
Years of drug use 14.5 (7.8) 3/37
Treatment attempts, n (%) 1.6 (2.4) 0/20
Inpatient/outpatient 75/51 –
All data are mean (SD), unless otherwise specified.
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previous treatment attempts varied (range ¼ 0–20), most
patients reported one or more previous treatment attempts.
3.2. Psychological distress at baseline (SCL-90-R)
Baseline SCL-90-R scores are summarized in Table 2. In
general, patients reported elevated levels of psychological
distress across all indices of the SCL-90-R. No gender differ-
ences were evident, but age (b¼0.07; 95% confidence
interval [CI]: 0.12– to 0.02; p¼ 0.006) and years of drug
use (b¼0.05; 95% CI: 0.01– to 0.10; p¼ 0.036) were
significantly associated with decreased scores on the SCL-90-
R GSI. There were no significant differences between
inpatient and outpatient participants in mean SCL-90-R
GSI scores.
3.3. The course of abstinence and drug use
Over the year, 22.7% (N¼ 32) reported stable abstinence,
22.7% (N¼ 32) reported unstable abstinence, and 54.6%
(N¼ 77) reported relapse. Details of alcohol or drug use
during the follow-up period are summarized in Table 3. In
the stable abstinence group, no data were missing by defin-
ition. Of the 32 participants in the unstable abstinence
group, 59.4% (N¼ 19) reported a single episode of substance
or alcohol use before the 3-month visit, and eight reported a
single episode of substance or alcohol episode before the 6-
month visit. Five patients who were abstinent at the 12-
month evaluation had missing data on the 3-month (N¼ 1)
or 6-month (N¼ 4) evaluation and had not responded to
the SMS tracker. These patients were categorized in the
unstable abstinence group because of the uncertain nature of
their drug use during follow up. Of the 77 patients catego-
rized as relapsed, 47 had relapsed after 3months and had
continued substance use until the final assessment at
12months. Ten participants had relapsed after the 6-month
visit and had continued substance use until the 12-month
evaluation. Six participants relapsed in between the 6-month
and the 12-month visits. Lastly, eight participants had a sub-
stance use episode in the first 3months, followed by a time
of abstinence and a final relapse before the 12-month assess-
ment. Six participants had missing data on either the 3-
month visit (N¼ 1) or the 6-month visit (N¼ 5).
At baseline, there were no significant differences between
these groups on demographic variables (data not shown).
On the SCL-90-R GSI, no overall significant differences
between these groups were evident at baseline. Patients
in the relapse group scored significantly higher on the
SCL-90-R Depression scale when compared to the Stable
abstinence group. No other significant group differences
were evident on SCl-90-R at baseline.
3.4. Course of SCL-90-R
All patient groups showed a significant GSI score reduction
from baseline to 3-month follow-up in the paired samples t-
test (stable abstinence, t¼ 4.2, p< 0.001, d¼ 0.66; unstable
abstinence, t¼ 3.7, p¼ 0.001, d¼ 0.74; relapse t¼ 2.2,
p¼ 0.033, d¼ 0.26). A similar analysis of the development
from baseline to 12months demonstrated a medium reduc-
tion in SCL-90-R for the stable abstinence group (t¼ 4.7,
p< 0.001, d¼ 0.68), a large reduction for the unstable
abstinence group (t¼ 5.8, p< 0.001, d¼ 1.11), and a small
reduction in SCL-90-R GSI score for the relapse group,
which did not reach statistical significance (t¼ 1.5,
p¼ 0.135, d¼ 0.25). The complete set of stratified mean
scores in the SCL-90-R subscales is available in the
Supplementary material.
The LMM analysis found a significant main effect of the
fixed effects time (F(3, 25) ¼ 25.3, p< 0.001), progression
type (F(2, 25) ¼ 13.0, p< 0.001), and the interaction for
progression type time (F(6, 25) ¼ 3.8, p¼ 0.001). The
fixed effects estimates are summarized in Table 4. The stable
abstinence group (b¼0.35; 95% CI: 0.60 to 0.09;
p¼ 0.007) had significantly lower scores on the SCL-90-R
GSI than the relapse group. This was supported by a signifi-
cant difference (p< 0.001) in the estimated marginal means
(EMM) between the two groups (stable abstinence, EMM ¼
0.55, 95% CI: 0.38–0.71; relapse, EMM ¼ 1.06, 95% CI:
0.95–1.17). The unstable abstinence group did not differ in
overall GSI score when compared with the relapse group
(B¼ 0.01, 95% CI: 0.24–0.26; p¼ 0.931), which was sup-
ported by similar EMM between the two groups (unstable
Table 2. Gender-stratified mean t-scores on ten symptom dimensions, and






Somatization 1.0 (0.7) 0.9 (0.7) 1.1 (0.8) 0.232
Compulsive behavior 1.5 (0.7) 1.5 (0.8) 1.6 (0.7) 0.216
Interpersonal sensitivity 1.3 (0.8) 1.2 (0.8) 1.3 (0.9) 0.487
Depression 1.4 (0.8) 1.3 (0.8) 1.5 (0.8) 0.199
Anxiety 1.3 (0.8) 1.3 (0.8) 1.4 (0.9) 0.428
Hostility 0.8 (0.8) 0.8 (0.8) 0.9 (0.9) 0.698
Phobic anxiety 1.0 (0.9) 0.9 (0.8) 1.1 (0.9) 0.285
Paranoia 1.1 (0.9) 1.1 (0.8) 1.2 (1.0) 0.489
Psychoticism 0.7 (0.6) 0.7 (0.6) 0.7 (0.6) 0.991
Additional 1.4 (0.8) 1.4 (0.8) 1.5 (0.9) 0.466
Global Severity Index 1.2 (0.6) 1.1 (0.6) 1.2 (0.7) 0.300
Positive symptom total 52.4 (19.5) 51.9 (20.1) 53.3 (18.5) 0.677
Positive symptom distress 1.9 (0.5) 1.8 (0.5) 2.0 (0.5) 0.164
SCL-90-R: Symptom Checklist 90 Revised.
All data are mean (SD), unless otherwise specified.
aGroup differences between male and female participants.
Table 3. Substance use during the follow-up period for the different
patient groups.
Category Substance usea N
Stable abstinence (N¼ 32) 0 0  0 0 32
Unstable abstinence (N¼ 32) 0 1  0 0 6
0 0  1 0 8
0 1  1 0 13
0  (M/1)  (M/1)  0 5b
Relapse (N¼ 77) 0 1  0 1 8
0 1  1 1 47
0 0  1 1 10
0 0  0 1 6
0  (M/1)  (M/1)  1 6c
a“0” indicates no substance use; “1” indicates positive substance use; M indi-
cates missing data.
bOne missing on 3-month visit, four missing on 6-month visit.
cOne missing on 3-month visit, five missing on 6-month visit.
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abstinence, EMM ¼ 0.86, 95% CI: 0.69–1.03; relapse,
EMM ¼ 1.06, 95% CI: 0.95–1.17; p¼ 0.152). The stable
abstinence group had significantly lower EMM scores than
the unstable abstinence group (stable abstinence, EMM ¼
0.55, 95% CI: 0.38–0.71; unstable group, EMM ¼ 0.86, 95%
CI: 0.69–1.03; p¼ 0.033).
The fixed effect of time was statistically significant, sug-
gesting a general decline in SCL-90-R scores across the
entire cohort from baseline to 3months (b¼0.19; 95% CI:
0.33 to 0.05; p¼ 0.010), and from baseline to 6months
(b¼0.43; 95% CI: 0.58 to 0.27; p< 0.001). The overall
change between baseline and the final 12-month follow-up
visit was not significant.
The interaction between progression groups and time
suggests that the stable abstinence group did not differ in
the development of GSI score over the first 3months when
compared with the relapse group (reference category).
However, the unstable abstinence group had a significantly
steeper decline in GSI score during this period. The groups
did not significantly differ during the baseline to 6-month
period. Finally, across the full 12-month follow-up period,
both the stable abstinence group (b¼0.41; 95% CI: 0.66
to 0.15; p¼ 0.002) and the unstable abstinence group
(b¼0.49; 95% CI: 0.74 to 0.23; p< 0.001) reported a
significantly greater reduction in GSI scores than the relapse
group. In an effort to ensure that our results was not
impacted by the inclusion of five participants with missing
data in the “unstable” group, we replicated the analysis with
these participants coded as “abstinent”. This change did not
significantly change our results.
The adjusted tradjectories of SCL-90-R GSI scores are
shown in Figure 1. Follow-up within-group LMMs revealed
that the stable abstinence group saw a significant reduction
in SCL-90-R GSI scores between baseline and 3-month fol-
low-up (EMM difference ¼ 0.37; 95% CI: 0.60 to 0.15;
p< 0.001), but no significant change between further follow-
ups (Figure 1, Panel A). For the unstable group, a similar
development was observed, with a significant change in
SCL-90-R GSI score from baseline to the 3-month follow-up
(EMM difference ¼ 0.51; 95% CI: 0.86 to 0.15;
p¼ 0.001), but no significant change between remaining vis-
its (Figure 1, Panel B). For the relapse group, the change
from baseline to 3-month visit was also significant (EMM
difference ¼ 0.23; 95% CI: 0.44 to 0.02; p¼ 0.026).
This was followed by no significant change from the 3- to 6-
month follow-up, but then an increase in SCL-90-R score
between the 6- and 12-month follow-ups (EMM difference
¼ 0.31; 95% CI: 0.08–0.53; p¼ 0.002), setting this group
apart from the others (Figure 1, Panel C).
4. Discussion
This paper investigated changes in psychological distress and
substance use over 12months in a patient cohort with poly-
substance use following admission to outpatient or inpatient
treatment. In our sample, the initiation of a new treatment
series was followed by a significant decline in psychological
distress during the first 3months, regardless of whether
patients were still using substances, across all recovery groups.
Lasting and stable abstinence during the follow-up period was
rare. In a clinical context, these findings highlight the import-
ance of providing close monitoring and support over time for
patients who aim to resolve their SUD. Our data clearly illus-
trate that episodes of drug or alcohol use during recovery are
the norm rather than the exception, as more than half of our
patients experienced a relapse at some point during the
12months following admission to treatment.
This study is one of only a limited number of studies
that have focused specifically on patients with PSUD. As
PSUD is the norm rather than the exception, this means
that the findings are likely to be relevant for a large propor-
tion of people in care for any SUD (McCabe et al. 2017).
Table 4. Fixed effects estimates in linear mixed regression model for SCL-90-R
GSI t-score from baseline to 12-month follow-up.
Outcome Fixed effect Estimates SE 95% CI
SCL-90-R Main effects group
Stable abstinence 0.34 0.13 0.6 to 0.1
Unstable abstinence 0.01 0.13 0.2 0.3
Relapse group 0 (ref)
Baseline 0 (ref)
3 months 0.19 0.07 0.3 to 0.1
6 months 0.42 0.08 0.6 to 0.3
12 months 0.10 0.07 0.2 0.0
Interaction, group time
Stable abstinence baseline 0 (ref)
Stable abstinence  3 months 0.21 0.13 0.5 0.1
Stable abstinence  6 months 0.05 0.14 0.3 0.2
Stable abstinence  12 months 0.41 0.13 0.7 to 0.2
Unstable abstinence baseline 0 (ref)
Unstable abstinence  3 months 0.31 0.13 0.6 to 0.1
Unstable abstinence  6 months 0.05 0.15 0.3 0.2
Unstable abstinence  12 months 0.49 0.13 0.7 to 0.2
Relapse time 0 (ref)
SCL-90-R GSI: Symptoms Checklist 90 Revised Global Severity Index; SE: stand-
ard error; CI: confidence interval.p< 0.05; p< 0.001.
Figure 1. Estimated marginal means of SCL-90-R GSI T-score during 12months of follow up. Footnote: Panel A is based on participants with stable abstinence;
Panel B is based on participants with unstable abstinence; and Panel C is based on patients with relapse.
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Previous studies have found that higher levels of pretreat-
ment mental distress and psychiatric disorders predict
relapse and these leading authors recommend screening for
psychological symptoms at the onset of treatment
(Andersson, Wenaas, et al. 2019). In our sample, however,
the relapse and unstable abstinence groups did not signifi-
cantly differ in initial psychological distress. Both groups
demonstrated an initially steep decline in psychological dis-
tress over the first 3months, although this effect was less
prominent among the relapse group. A similar pattern was
found in a previous study that identified alleviation of men-
tal distress after 1month of follow-up (Gossop et al. 2006).
These findings suggest that alleviation of psychological dis-
tress is commonplace when initiating a new treatment
sequence. This aspect of recovery may be due to abstinence
alone. However, psychological (for example personality
traits, intelligence or self-efficacy) or demographic factors
(for example housing, job security, familial support) may
contribute, alongside regression to the mean, to the decline
of psychological distress (Daughters et al. 2005; Dennis et al.
2007; Hoxmark et al. 2010).
The decline in psychological distress at 3-month follow-
up could be due to a greater degree of abstinence among all
of the groups at the beginning of treatment. However, the
reduction in psychological distress among the unstable
group persisted throughout the 12months. Only the relapse
group had an increase in psychological distress back to base-
line levels at the 12-month evaluation. This finding is some-
what surprising, given previous reports that successful
abstinence is related to more prominent alleviation of psy-
chological distress and increased quality of life during recov-
ery from SUD or alcohol use disorder (Subbaraman and
Witbrodt 2014; Andreas et al. 2015). Our study suggests that
reductions in mental distress may be persistent even if epi-
sodes of substance use occur during the recovery process.
The current findings are important because they indicate
that no abstinence period is without positive effects on the
reduction of psychological distress.
The observation that symptoms of psychiatric distress
improve with time during treatment for PSUDs has historic-
ally been taken as evidence that psychiatric disorders in peo-
ple with PSUDs are generally substance-induced and need
not to be urgently addressed (see Delgadillo et al. 2016 for a
critique). Patients with high levels of psychological distress
have an increased risk of relapse or drug use during the
recovery phase (Flynn et al. 2004; Andersson, Steinsbekk,
et al. 2018), or an ongoing need for treatment for psychiatric
disorders (Thylstrup et al. 2018). Hence, early screening is
not without its merits. Indeed, frequent monitoring of drug
use and psychological distress may also have clinical value
by allowing early identification of relapse episodes and inter-
ventions timed to the patient’s specific status concerning
drug use and psychological distress (Dennis and Scott 2007).
In this study, 45.4% of participants reported being abstin-
ent 12months after the onset of treatment. It is sobering to
note, however, that only 22.7% of participants, all of whom
started a new treatment sequence, managed to stay abstinent
throughout the full year. This is supported by clinical
observations, and findings from other longitudinal studies
investigating the recovery process in these patients (Vaillant
1988; Dennis and Scott 2007). Indeed, a recent meta-analysis
showed that complete remission from substance use is rare,
and expected in only 10–15% of cases per year (Fleury
et al. 2016).
These findings highlight the continued importance of
early screening for psychological distress to tailor support
and monitoring levels during treatment. This is especially
important for patients who report lower rates of symptoms
alleviation during the first 3months of treatment, and thus
pose a greater risk of substance use episodes. Still, in clinical
practice patients with comparatively mild levels of psycho-
logical distress are not guaranteed a stable or even successful
recovery. Indeed, patients with PSUD may not only be in
need of continued support and monitoring during the recov-
ery phase, but may also need to have easy access to re-
admission after episodes of relapse. Finally, our findings also
highlight the importance of continued care for patients who
have episodes of drug use during treatment, since single epi-
sodes of drug use during recovery do not always entail con-
tinued substance use. In clinical practice, this new
knowledge could inform psychoeducation about the expected
mental health benefits of abstinence.
4.1. Strengths and limitations
The major strengths of this study are its prospective design,
participants recruited from multiple treatment settings, fre-
quent and repeated assessments during the 12-month fol-
low-up period, and the relatively low level of attrition
during follow-up. The study also utilizes validated scales that
are common in clinical practice in the follow-up of patients
with PSUD.
An important limitation to our study is that some partici-
pants missed follow- up visits. Missing data is common in
addiction research, and we have used two strategies to han-
dle this issue. First of all, LMM handles missing data well
and is an overall better statistical strategy for longitudinal
data, as it avoids list-wide deletion or imputation of data,
which is common in many SUD studies (McPherson et al.
2012). Secondly, the inclusion of an SMS tracker provides
strong temporal insights into the SUD status for participants
with missing data. This yields a more accurate depiction of
drug and alcohol use across the follow-up period. Our rela-
tively low attrition rate (6.7%) also increases the external
validity and generalizability of our data. A further limitation
of this study is that SUD outcome groups are based on self-
report. Self-report has been shown to be a feasible instru-
ment for the study of SUD populations (Secades-Villa and
Fernandez-Hermida 2003). Still, this issue could be at least
partly resolved in future studies with somatic screening (e.g.
urine samples) and/or collateral information from next-of-
kin or treatment practitioners to substantiate group categor-
ization. Lastly, the data is based on a convenience sample,
where clinicians asked relevant patients to participate in the
study. However, the universal access to health care and
treatment in Norway probably allows a more comprehensive
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sample relative to countries where care is privatized
and costly.
Future prospective studies could include an additional
measure of psychological distress tolerance to provide fur-
ther insight into possible the associations between a higher
degree of psychological distress and vulnerability to the risk
of relapse/increased drug use (Daughters et al. 2005).
4.2. Conclusions
Psychological distress in PSUD participants significantly
declined during the first 3months of abstinence in treat-
ment. However, there is no straightforward correlation
between abstinence and psychological distress: Short-term
alleviation of distress may exist even alongside temporary
relapse episodes. Still, our data show that a return to abstin-
ence after using is necessary to attain long-term alleviation
of mental distress. These findings argue for the importance
of continued follow up when patients relapse dur-
ing treatment.
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